10x Genomics

Update in progress

TXG (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its Chromium platform enables single‑cell analysis with microfluidic chips and X Series instruments, plus QuantumScale kits for RNA and methylation. Visium provides spatial analysis with HD panels and CytAssist. Xenium Analyzer detects RNA targets in tissue. Software includes Cell Ranger, Loupe Browser, and Xenium Explorer. Serves academia, government, and industry. Based in Pleasanton, CA. Established 2012; renamed 10x Genomics in 2014.

Company score

Sentiment: 0.61; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.09; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.52; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.37; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive